FDA hands down a par­tial hold for PhI/II tri­al of Blue­print’s CDK2 in­hibitor

The FDA is giv­ing one of Blue­print Med­i­cines’ tri­als a par­tial clin­i­cal hold.

On Fri­day, the Mass­a­chu­setts-based biotech said the FDA in­formed Blue­print two days ago that it is plac­ing a par­tial hold on a Phase I/II study, al­so known as the VELA tri­al, look­ing at BLU-222 in ad­vanced sol­id tu­mors. The par­tial hold was due to ad­verse events be­ing ob­served in a “lim­it­ed num­ber” of pa­tients, Blue­print said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.